Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.54 |
| ▸ | TLR2 | O60603 | 1/20 | 0.54 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.54 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535289 | 0.81 | ALDH1A1 (0.44) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1527154 | 0.80 | ERN1 (0.69) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL13605931 | 0.77 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL8043039 | 0.77 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL5074569 | 0.76 | TUBB1 (0.54) | — | |
| SCHEMBL5074564 | 0.76 | TUBB1 (0.54) | — | |
| SCHEMBL28901718 | 0.76 | ERN1 (0.54) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL93023 | 0.76 | CA1 (0.54) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL6861276 | 0.75 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL195007 | 0.75 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004078261-A1 | CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2004-09-16 | — | — | WO | disclosed |